

**State and Public School Life and Health Insurance Board  
Clinical and Fiscal Drug Utilization and Evaluation  
Committee**

**Minutes  
November 24, 2009**

*Teleconference*

The State and Public Life and Health Insurance Board, Drug Utilization and Evaluation Committee (DUEC) met on Monday, November 24, 2009 at 2:30 p.m., via-teleconference.

**Members present:**

Dr. William Golden  
Matthew Hadley  
Kat Neill  
Larry Dickerson  
Hank Simmons

**Members absent:**

Mark McGrew  
Robert Watson  
Dr. James Bethea  
Dr. Joe Stallings, Jr.

Jason Lee, Executive Director, Employee Benefits Division of DFA.

**Others Present**

Barry Fielder, NMHC; Jill Johnson, UAMS College of Pharmacy/EBRx; Lori Eden, Sherry Bryant, Sherry Saxby, Jane Young, Cathy Harris, EBD;

**Call to Order**

Meeting was called to order by Dr. Golden.

**Votrient**

Votrient (pazopanib) is a new drug used for the treatment of advanced renal cell carcinoma.

The following recommendation for the Board consideration resulted from that meeting.

**Recommendation:** approve the drug Votrient at the tier 3 level for a two week increments subject to prior authorization (PA) criteria that correspond with the FDA indications.